Effect of capecitabine on mean corpuscular volume in patients with metastatic breast cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 27, Issue 4, 2004, Pages 364-368

  Karvellas, Constantine J ^a   Sawyer, Michael ^b   Hamilton, Marlene ^a   Mackey, John R ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b CROSS CANCER INSTITUTE   (Canada)

Author keywords

Anemia; Breast cancer; Capecitabine; Macrocytosis; Thymidylate synthase

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; FLUOROURACIL; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; BLOOD CELL COUNT; BONE MARROW SUPPRESSION; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; DOSE TIME EFFECT RELATION; FEMALE; HUMAN; LIVER DYSFUNCTION; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MEAN CORPUSCULAR VOLUME; MEGALOCYTOSIS; METASTASIS; NEUTROPENIA; RETROSPECTIVE STUDY; REVIEW; THROMBOCYTOPENIA;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BREAST NEOPLASMS; DEOXYCYTIDINE; ERYTHROCYTE INDICES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PRODRUGS; RETROSPECTIVE STUDIES;

EID: 3843112584     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.COC.0000071464.83271.08     Document Type: Review

References (16)

1. Miwa M, Ura M, Nishida M, et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-81.
2. Blum JL, Jones SE, Buzdar AU, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-93.
3. Grem JL, McAtee N, Balis F, et al. A phase II study of continuous infusion 5-fluorouracil and leucovorin with weekly cisplatin in metastatic colorectal carcinoma. Cancer 1993;72:663-8.
4. Twelves C, Glynne-Jones R, Cassidy J, et al. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites. Clin Cancer Res 1999;5:1696-702.
5. Lee GR. Megaloblastic and nonmegaloblastic anemias. In: Lee GR, Bithell TC, Foerster J, et al., eds. Wintrobe's clinical hematology, 9th ed. Philadelphia: Lea & Febiger, 1993:770-1.
6. Metz J. The deoxyuridine suppression test. Crit Rev Clin Lab Sci 1984;20:205-41.
7. Wickramasinghe SN. The wide spectrum and unresolved issues of megaloblastic anemia. Semin Hematol 1999;36:3-18.
8. Brennan M, Waitkevicius V, Rebuck J. Megaloblastic anemias associated with inhibition of thymine synthesis (observations during 5-fluorouracil treatment). Blood J 1960;14:1535-45.
9. Lokich JJ, Ahlgren JD, Gullo JJ, et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-32.
10. Dolnick BJ, Cheng Y. Human thymidylate synthetase derived from blast cells of patients with acute myelocytic leukemia. Purification and characterization. J Biol Chem 1977;252:7697-703.
11. Dolnick BJ, Cheng YC. Human thymidylate synthetase. II. Derivatives of pteroylmono- and -polyglutamates as substrates and inhibitors. J Biol Chem 1978;253:3563-7.
12. Horie N, Aiba H, Oguro K, et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5′-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995;20:191-7.
13. Iacopetta B, Grieu F, Joseph D, et al. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001;85:827-30.
14. Pullarkat ST, Stoehlmacher J, Ghaderi V, et al. Thymidylate synthase gene polymorphism determines response and toxicity of 5-FU chemotherapy. Pharmacogenomics J 2001;1:65-70.
15. Maruyama F, Ezaki K, Okamoto M, et al. Increased blood cell destruction during vigorous regeneration of bone marrow after intensive chemotherapy for non-Hodgkin lymphoma. Eur J Cancer 1993;29A:1499.
16. Van Cutsem E, Twelves C, Cassidy J, et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. J Clin Oncol 2001;19:4097-106.